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Explanatoty Memorandum 
1. In Art. 9 and 10 of Directive 75/319/EEC of 20 May 1975 on the 
approximation of provisions laid down by law, regulation or 
administrative action relating to proprietary medicinal products 
(O.J. L 147 of 9 June 1975) it is stated that a Member State which 
has issued a marketing authorization for a proprietary medicinal 
product shall forward to the Committee a copy of the authorization 
together with the documentation material if the person responsible 
for marketing has required to apply for marketing authorization 
for the product in at least five other Member States through the 
Committee procedure. The Committee shall hereafter without delay 
retransmit the dossiers to the Member States specified which trans-
mission shall be deemed equivalent to a fomal application for 
• :·marketing authorization. ,·~ ... 
2. Daring the discussions on the Rules of Procedure within the Committee 
it has become clear that the obligation that the dossiers in all 
cases shall pass through .. the . Commi .re e.e instead of beiri{:~ent directly 
to the Member States concerned. will give rise to severe administrative 
problems for the Secretariat::a.nd be very time consuming as the dossiers 
are often very voluminous. In addition to this, the Secretariat ·or 
the Committee will not carry out any examination of the dossiers before 
the transmission to the Member States. 
3. It is therefore proposed (see annex) to amend Art. 9 and 10 of Directive 
15/319/EEC so that the dossiers will be forwarded directly to the 
Member States specified by the Member State which has already granted 
the marketing authorization. 
4• The Pharmaceutical Committee set up by Council Decision 75/320/EEC 
has agreed in principle on the amendment and the present te:x:t has got 
unanimous approuva.l by a working party of national experts on 
29 June 1977. ~ .. ·.·. 
PROPOSAL FOR A COUNCIL DIRECTIVE 
amending Second Directive 75/319/EEC on the approximation of provisions 
Laid down by Law; regulation or administrative action relating to 
proprietary medicinal products 
THE COUNCIL OF THE EUROPEAN COMMUNITIES, 
Having regard to the Treaty establishing the European Economic Community, 
and in particular Article 100 thereof, 
Having regard to the proposal from the Commission, 
Having regard to the Opinion of the European Parliament (1), 
Having regard to the Opinion of the Economic and Social Committee (2), 
Whereas, a Committee for Proprietary Medicinal Products has been set up 
by Second Council Directive 75/319/EEC of 20 Mai 1975 (3) with the 
responsibility to give an opinion as to whether a particular proprietary 
medicinal product complies with the requirements set out in Council Directive 
65/65/EEC of 26 January 1965 on the approximation of provisions laid down 
by law, regulation or administrative action relating to proprietary medicinal 
products (4); 
Whereas it is stated in Articles 9 and 10 of Directive 75/319/EEC that, 
in cases where the Community-procedure is to be applied, the Member State 
which has issued the marketing authorization shall forward the dossier 
·to the Committee which shall forthwith forward the dossier to the Member 
States specified by the person responsible for marketing; 
Whereas experience has shown that the provision that the dossiers shall pass 
through the Committee instead of being sent direct(y to the Member States 
concerned results in administrative problems in processing the voluminous 
documentation and in delays in the work of the Committee; 
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rlhercas! in order to solve these problems and to reduce the delays it is 
· necessary to amend 1ihese provisions to enable the !!.ember State which 
has initially issued the marketing authorization to send the dossier 
directly to the lJiember States specified as ~-;ell as to the Committee. 
- 3-. 
HAS ADOPTED THIS DIRECTIVE: 
Article 1 
Article 9 of Directiv·e 75/319/EEC is hereby-amenEled 
as follovm: 
1. The Member State v1hich has issued a marketing authorization. for 
a proprietary medicinal product shall forward, if the person 
respon3ible for marketing has reques·t;ed the for(1arding to at lea3t 
five other Member States, a dossier containing a copy of this 
request and a copy of the authorization together •·li th the particul.:::.rs 
and documents mentioned in Article 4, second paragraph of Directive 
65/65/EEC to the Committee and to the competent authorities of the 
:Member States specified. 
2. Such forv1arding shall be deemed to be equivalent to submitting an 
application for marketing authorization, •nthin the meaning of 
Article 4 of Directive 65/65/EEC, to the said authorities. 
3. The Committee shall forthwith inform the Member States concerned 
that the case has been referred to the Committee. 
Article 2 
In .Article 10 \1) of Directive -?S/319/EEC--the words "forward1ng referred 
toin Article 9 (2)" are hereby replaced by "transmission of the information 
referred to in Article 9 (3)". 
Article 3 
'l"~'nis Directive is addressed to the Member States. 
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